Martin Reck, MD, PhD, on SCLC: Maintenance Therapy for Patients With Extensive-Stage Disease
IASLC 2020 World Conference on Lung Cancer in Singapore
Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).
Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).
Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved communities in clinical trial research (Abstract PL04.06).
Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describes her family history of cancer, how she has worked with her physicians for more than a decade to survive her own diagnosis, and the message she would like all oncologists to hear.
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated non–small cell lung cancer; and patient-reported outcomes, which showed a benefit in disease-free survival and maintenance of health-related quality of life in patients with resected stage IB to IIIA disease (Abstracts OA06.04 and OA06.03).
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of mesothelioma is on the rise; in the United Kingdom alone, it has gone up nearly 500% since the 1970s (Abstract PS01.11).